BIO Reiterates Support for 12-Year Data Exclusivity Period for Biologics

by McDonnell Boehnen Hulbert & Berghoff LLP
Contact

Biotechnology Industry Organization (BIO)Last month, in a letter to the U.S. Trade Representative, Ambassador Michael Froman, Biotechnology Industry Organization (BIO) President and CEO James Greenwood expressed support for the efforts of the Obama Administration to develop a "comprehensive, forward-looking Trans-Pacific Partnership (TPP) agreement."  The Trans-Pacific Partnership Agreement (TPP) is a multilateral free trade agreement currently being negotiated by Australia, Brunei, Chile, Malaysia, New Zealand, Peru, Singapore, the United States, and Vietnam (Canada, Japan, the Philippines, South Korea, and Taiwan have also expressed interest in participating in the agreement).

Accompanying Mr. Greenwood's letter was a white paper, entitled "The Trans-Pacific Partnership and Innovation in the Bioeconomy: The Need for 12 Years of Data Protection for Biologics," which Mr. Greenwood indicated "provides a comprehensive overview of the considerations related to an area of critical importance to our members -- effective legal protections for innovative biological pharmaceutical products."  Noting that the U.S. enacted a biosimilar regulatory pathway (the Biologics Price Competition and Innovation Act (BPCIA)) as part of the Patient Protection and Affordable Care Act (PPACA), the letter states that the U.S. regulatory pathway "was developed after extensive deliberations by the United States Congress, and balances a number of critically important considerations, particularly the need to provide a continued, robust incentive for development of new biological products and new uses of existing products."  Mr. Greenwood urged Ambassador Froman "to draw from this record of experience in developing the U.S. system as you engage in deliberations with other TPP countries to fashion international standards that will relate to these products and our industry."

The 40-page white paper accompanying Mr. Greenwood's letter, which was prepared by BIO, notes that "[t]he biotechnology industry is one of the most research-intensive industries," adding that "[t]he vast majority of biotechnology companies are small, start-up companies that are heavily reliant on private investment capital, lack revenues from marketed products, and operate in financial loss positions."  According to the paper, "on average, [it takes] more than a decade and in excess of $1.2 billion to bring a biological product to market."  Because biologic drugs are complex and more difficult to manufacture than small molecule drugs, "[t]hey present unique considerations relative to pharmaceutical products containing active ingredients made by traditional chemical synthesis."

One of those unique considerations involves the ability of innovators to obtain adequate patent protection for biologic drugs.  In particular, because a generic biologic -- or biosimilar -- does not have to be identical to a biologic, "there is greater uncertainty as to whether an innovator's patent rights will cover a biosimilar version of the innovator’s product, as compared to a traditional generic drug."  The paper contends that "[w]ithout the certainty of some substantial period of market exclusivity, innovators will not have the incentives needed to conduct the expensive, risky, and time-consuming work to discover and bring new biological products to market."  The paper also indicates that the legislative process that resulted in enactment of the BPCIA was "deliberate, thoughtful, and driven by rigorous analysis," and points out that "[e]xtensive research by noted economists demonstrated that developers of innovative biological products require a period of market exclusivity of between 12 and 15 years simply to break even on their investments in developing a new biological product."

The paper argues that "[t]o encourage continued development of innovative biological vaccines and therapies, it is critically important to implement effective standards of IP protection within the TPP region."  BIO's white paper contends, therefore, that "[i]t is imperative that the TPP create a set of strong intellectual property standards -- particularly those governing data protection, patents and trade secret protection -- that are relevant to biological products."

For additional information regarding this topic, please see:

* "Senators Back 12-Year Data Exclusivity Period for Biosimilars and President Obama (Once Again) Does Not," May 9, 2013
• "U.S. Negotiators on TPP -- Don't Trade Away the Biopharmaceutical Research Sector," September 30, 2012
• "Senators Support Inclusion of 12-Year Exclusivity Period in Free Trade Agreement," September 12, 2011
• "House Legislators Lobby to Exclude 12-Year Data Exclusivity Period from Free Trade Agreement," August 11, 2011

 

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDonnell Boehnen Hulbert & Berghoff LLP | Attorney Advertising

Written by:

McDonnell Boehnen Hulbert & Berghoff LLP
Contact
more
less

McDonnell Boehnen Hulbert & Berghoff LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
Feedback? Tell us what you think of the new jdsupra.com!